人乳头瘤病毒（HPV）疫苗的研究进展

nce.Journal of Clinical Virology，2000，19:1-5. 3 李忠明.当代新疫苗，北京:高等教育出版社，2001，66. 4 S.H.Vander，Burg.Preclinical safety and efficiency of TA-CIN，a r eˉcombinant HPV16L2E6E7fusion protein vaccine，in homlolgous and heter lolgous primeboost regimens.Vaccine，2001，19:3652-3600. 5 Kirnbaner R，booy F，Cheng N，et al.Papillomavirus L1major capsid protein self-assembles into VLP that are highly immunogenic.Proc Natl Acad Sci USA，1992，89:12180-12184. 6 Sasagawa T，Pushko P，Steers G，et al.Synthesis and assembly of v irus-like particles of human papillomaviruses type6and type16in fission yeast Schizosaccharomyces pombe.Virology，1995，206:126-135. 7 Kirnbaner R，Booy F，Cheng N，et al.Papillomavirus L1major capsid protein self-assembles into VLP that are highly immunogenic.Proc Natl Acad Sci USA，1992，89:12180-12184. 8 Muller M，gissman L，Cristiano RJ，et al.Papillomavirrus capsid b inding and uptake by cells from different tissues and species.J Virol， 1995，69:948-954. 9 Harro CD，Pang YS，Roden RBS，et al.Safety and immunogenicity tri al in adult volunteers of a human papillomavirus16L1virus-like particle vaccine.Journal of the National Cancer Institue，2001，93:284-292.　　10 Lehtinen M，Dillner J.Preventivehuman papillomavirus vaccination .Sex Tansm Inf，2002，78:4-6. 11 Koutsky LA，Ault KA，Wheeler CM，et al.A controlled trial of a h uman papillomavirus type16vaccine.The New Englang Journal of Medicine， 2002，347:1645-1651. 12 Mu7ller M，Zhou J，Reed TD，et al.Chimeric papillomavirus-like p artickes.Virology，1997，234:93-111. 13 Roden RC，Hubbert NL，Kirnbauer R，et al.Assessment of the serol ogiˉcal relatedness of genital human papillomaviruses by hemagglutinat ion inhibition.J Virol，1996，70:3298-3301. 14 DUpuy C，Buzoni-Gatel D，Touze A，et al.Nasal immunization of mi ce with HPV-16VLP or with the HPV-16L1gene elicits specific cytotocxic T lymphocytes in vaginal draining lymph nodes.J Virol，1999，73:9063-90 71. 15 Gallichan W.S，rosethal K.L.Specific secretory immune responses in the female genital tract following intranasal immunization with a re comˉbinant adenovirus expressing blycoprotein B of HSV.Vaccine，1995， 13:1589-1595. 16 Shi W，Bu P，Liu JZ，et al.HPV16E7NDA vaccine:mutation in the op enreading frame of E7enhances specific cytotoxic T lymphocyte inˉducti on and antitumor activity.J of Virology，1999，73:7877-7881.　　17 Suezanne E，Parker.Pasmid DNA malaria vaccine:tissue distributio n and safety studies in mice and rabbits.Human Gene Therapy，1999，10:7 41-758. 18 Hanke T，McMichael A.J，Samuel Rv，et al.Lack of toxicity and pe rˉsistence in the mouse associated with administration f candidate DNA and modified vaccinia virus Ankara（MVA）-based HIV vaccines for Kenya .Vaccine，2002，21:108-114. 　 19 Gao L，Chain B，Sinclair C，et al.Immune response to human papil loˉmavirus type16E6gene in a live vaccinia vector.Journal of Gene

《人乳头瘤病毒（HPV）疫苗的研究进展(第3页)》